Investment Rating - The report maintains an investment rating of "Outperform the Market" [4] Core Insights - The report highlights the promising data disclosure of PD-L1 ADC HLX43 by Fuhong Hanlin at WCLC 2025, indicating its potential as a superior treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have failed standard therapies [2][3][18] - The report suggests that there are multiple upcoming catalysts in the sector, including academic conferences, business development (BD) opportunities, and negotiations for medical insurance and innovative drug directories [2][18] Summary by Sections Weekly New Drug Market Review - From September 1 to September 7, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+62.01%) - Chuangsheng Group (+47.26%) - Jakes Pharmaceuticals (+40.69%) - Hualing Pharmaceutical (+30.90%) - Yiming Oncology (+28.26%) - The top five decliners were: - Frontier Biopharmaceuticals (-10.47%) - Kemia (-9.09%) - Zai Lab (-5.62%) - Ascentage Pharma (-4.57%) - Yundin New Medicine (-4.56%) [1][14] Weekly Focused Stocks - The report recommends focusing on several companies with upcoming data disclosures, including Fuhong Hanlin, Baillie Tenheng, and Kangfang Biopharmaceuticals, which are expected to provide significant updates [2][18] - Potential heavyweights for overseas licensing include differentiated GLP-1 assets from companies like Zhongsheng Pharmaceutical and Gilead Sciences, as well as upgraded PD-1 products from Kangfang Biopharmaceuticals [2][18] Weekly New Drug Industry Analysis - Fuhong Hanlin's PD-L1 ADC HLX43 has shown excellent efficacy in treating NSCLC, with an overall objective response rate (ORR) of 37.0% and a disease control rate (DCR) of 87.0% in the overall NSCLC population [19][20] - The data indicates that HLX43 has the potential to expand into frontline treatment and combination therapy [2][18] New Drug Approval and Acceptance Status - This week, three new drug applications were approved, including: - Fuhong Hanlin's new drug for NSCLC - Merck's Letermovir tablets - Sanofi's Tislelizumab injection - Eleven new drug applications were accepted for review [24][25] Weekly New Drug Clinical Application Status - Twenty new drug clinical applications were approved this week, with fifty-eight applications accepted for review [27]

Core Viewpoint - HengRui Medicine has entered into an exclusive licensing agreement with Braveheart Bio for the development and commercialization of its proprietary Myosin small molecule inhibitor HRS-1893 outside of Greater China [1] Group 1: Licensing Agreement Details - HengRui Medicine grants Braveheart Bio exclusive rights to develop, manufacture, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - Braveheart Bio will pay a total of $75 million, which includes a $65 million upfront payment ($32.5 million in cash and $32.5 million in Braveheart Bio equity) and a $10 million milestone payment upon completion of technology transfer [1] Group 2: Potential Financial Gains - HengRui Medicine is eligible to receive up to $1.013 billion in milestone payments related to clinical development and sales, along with corresponding sales royalties [1]

Summary of Conference Call Notes Company and Industry Overview - **Company**: 长春高新 (Changchun High-tech) - **Industry**: Pharmaceutical and Biotechnology Key Points and Arguments Strategic Transformation and R&D Investment - 长春高新 is undergoing a strategic transformation with increased R&D investment, which has led to short-term performance pressure but is showing innovation results, particularly in AI-assisted R&D and products in the women's and children's health sectors [2][5][4] - The company has invested over 1.3 billion yuan in R&D in the first half of 2025, a 13% year-on-year increase, accounting for over 20% of revenue [4] Growth Logic of 金赛药业 (Jinsai Pharmaceutical) - The future growth logic of 金赛药业 includes three main drivers: overseas licensing of innovative drugs, new revenue sources, and traditional growth hormone business [2][6] - The company aims for overseas revenue to exceed 50% within 3-5 years, transitioning from a domestic focus to an international market [6] Product Developments and Market Potential - 福星 700单抗 (Fuxing 700 monoclonal antibody) has been approved for gout treatment, with a broad application range and high compliance, showing significant market potential [2][8] - The women's health business is expected to grow rapidly, with sales projected to approach 1.5 billion yuan next year, supported by the launch of long-acting follicle-stimulating hormone [10] - 美施亚 (Meishiya) products for cancer cachexia treatment are expected to have a market value of approximately 25 billion yuan, with good market response [2][13] Competitive Landscape and Pricing Strategy - The growth hormone market faces increased competition, prompting the company to adjust pricing strategies to cover a broader market and maintain a competitive edge [16][48] - The company is proactively addressing challenges posed by economic conditions and competition, ensuring continued leadership and cash flow stability [16][48] Future Profit Growth Trends - 金赛药业 anticipates profit growth in the next three years, with overseas licensing and new business profits expected to surpass contributions from growth hormones by 2027 [7] - The company plans to leverage new product launches and overseas licensing to offset any declines in growth hormone sales [48] R&D Pipeline and Clinical Trials - 金赛药业 has a robust pipeline with 35-36 molecules expected to enter the IND stage by the end of 2027, focusing on innovative drug development [3][43] - The company is committed to maintaining high-quality R&D through strong clinical operations and technology platforms [22][25] Market Position and Future Outlook - 金赛药业 holds a leading position in China's innovative drug market, being one of the first companies to scale up innovative drug development [20][21] - The company aims to ensure its innovative drugs remain industry leaders through continuous R&D investment and strategic partnerships [24][25] Financial Guidance and Strategic Adjustments - The company expects a significant adjustment in performance for 2025, with a focus on stabilizing cash flow through new business profits and overseas licensing [53] - Future strategies will emphasize clinical operations to maximize the success rate of IND submissions and enhance product value [62] Conclusion and Leadership Vision - Company leadership expresses confidence in the strategic adjustments made over the past few years, aiming for a stable growth trajectory driven by innovative drugs and a diversified product portfolio [68] Additional Important Information - The company plans to enter the gynecology market with a series of diagnostic and therapeutic products, enhancing its women's health business [10] - The development of ADC (antibody-drug conjugates) products is a key focus, with several innovative candidates in the pipeline targeting various cancers [29][55]

J P M O R G A N Asia Pacific Equity Research 25 August 2025 This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. Hengrui - A 1H25 print continuing to suggest strong fundamentals; Maintain Neutral on valuation Hengrui delivered a solid print for 1H25 (our first ta ...

Summary of the Conference Call for 恒瑞医药 Company Overview - **Company**: 恒瑞医药 (Hengrui Medicine) - **Industry**: Pharmaceutical Key Points and Arguments Financial Projections - Expected domestic sales revenue growth of over 15% in 2025, with innovative drugs growing over 25% and generic drugs stabilizing [2][5] - Anticipated overseas licensing revenue exceeding $500 million, with total revenue growth projected at over 19% [2][5] - Net profit expected to reach 8.7 billion RMB, a year-on-year increase of 38% [2][5] Innovation and Product Pipeline - Focus on innovative drugs as a key growth driver, with several major products and indications launched, such as 白介 17, Jack one, and HER2 ADC [2][6] - Projected sales for innovative drugs to reach 17.4 billion RMB in 2025, contributing over 3.4 billion RMB to net profit [2][6] - R&D pipeline includes over 30 projects ranked in the top three globally, enhancing market competitiveness and valuation flexibility [2][7] International Expansion - Multiple overseas projects in progress, including a $200 million LPA project and 11 preclinical projects worth $500 million [2][9] - Expected BD (business development) revenue to exceed $575 million in 2025, contributing over 3 billion RMB to profits [2][9] Investment Logic - Investment logic based on three pillars: 1. Product harvest period leading to accelerated internal growth and valuation recovery [3] 2. Overseas market as a second growth curve with sustainable revenue potential [3] 3. Early-stage R&D pipeline targeting best-in-class or first-in-class products [3] Competitive Landscape - Transition from a fast-follow strategy to a best-in-class and first-in-class approach, with a competitive edge in ADC (antibody-drug conjugate) products [3][12] - Significant advancements in ADC products, with global clinical progress ranking among the fastest [21][20] Market Dynamics - Domestic market expected to achieve significant growth over the next three years, driven by the approval of heavyweight products [14] - The company’s innovative drug sales are projected to maintain a rapid growth trend, supported by favorable policy changes [6][14] R&D Efficiency - R&D expense ratio reached a historical high in 2024, with expectations for improvement in efficiency and a stable ratio around 20% in the future [8][31] - Enhanced R&D efficiency is anticipated to drive net profit growth faster than revenue growth [8] Valuation Model - Valuation model includes six components: 1. PE valuation for generic drugs 2. PS valuation based on peak sales for innovative drugs 3. PS valuation for early-stage pipeline 4. PS valuation for overseas projects 5. Potential overseas market space 6. Best-in-class and first-in-class product potential [30] Future Growth Drivers - Key factors influencing future market performance include product performance, successful international expansion, and the realization of early-stage pipeline value [31] Additional Important Insights - The company has established a strong presence in four major therapeutic areas: oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [18] - Continuous exploration of various internationalization models, including partnerships and direct licensing [15][17] - The company’s innovative strategies in treating diseases like psoriasis and KRAS-targeted therapies demonstrate a deep understanding of disease mechanisms [29][22] This summary encapsulates the essential insights from the conference call, highlighting the company's growth strategies, financial outlook, and competitive positioning within the pharmaceutical industry.

Fixed Income - The bond market is under pressure from three main factors: rising industrial commodity prices due to "anti-involution" sentiment, a bullish stock market diverting funds away from bonds, and marginal improvements in economic indicators increasing market risk appetite [2][7][10] - As of July 25, 2025, the yields on various bonds, including government and corporate bonds, have risen significantly, indicating a market adjustment [2][7] - The report suggests a short-term bullish outlook for the bond market, with a potential return of the 10-year government bond yield to around 1.65% [10] Non-Banking Financials - The insurance industry is adjusting the maximum preset interest rates for life insurance products, with the new maximum for ordinary life insurance set at 2.0% and for participating insurance at 1.75% [12][13] - This adjustment is expected to lower the liability costs for insurance companies and encourage a shift towards participating insurance products, which have floating interest characteristics [13] - The report recommends companies like China Life, Ping An, and China Pacific Insurance, which have favorable asset-liability duration matching [13] Transportation - The express delivery industry is experiencing a shift towards value reassessment due to the "anti-involution" trend, which aims to protect the rights of delivery personnel and promote price increases across the industry [15][16] - The report highlights the potential for price improvements in the short term, especially in regions where delivery companies are currently facing losses [17] - Long-term prospects suggest a transition from price wars to value competition, which could enhance the performance of express delivery companies [17] Pharmaceuticals - Heng Rui Pharmaceutical has entered a significant partnership with GlaxoSmithKline (GSK) for the global licensing of its innovative drug HRS-9821, with potential milestone payments totaling approximately $12 billion [19][20] - The company is expected to see substantial revenue growth driven by its innovative drug pipeline, with projected net profits increasing significantly over the next few years [21][22] - The collaboration with GSK is anticipated to enhance Heng Rui's valuation and market presence, particularly in the respiratory field [20][21] New Consumption - Lao Pu Gold has projected impressive sales growth for the first half of 2025, with expected revenues between RMB 138 billion and 143 billion, reflecting a year-on-year increase of approximately 240% to 252% [24][25] - The company's brand influence and product optimization are key drivers of this growth, positioning it well in the high-end ancient gold market [25][26] - The ancient gold sector is expected to see strong growth, with a projected market size of RMB 2.193 trillion by 2024 and a compound annual growth rate of 21.8% from 2023 to 2028 [25][26]

Group 1 - The core viewpoint of the report is that Zhongtai International has upgraded the rating of Hansoh Pharmaceutical (03692) to "Buy" and raised the target price to HKD 29.30, reflecting positive sales contributions from overseas markets [1] - The sales revenue forecasts for 2025-2027 have been adjusted upward by 0.2%-0.6%, while total revenue forecasts have been increased by 1.2%-3.7%, and net profit forecasts for shareholders have been raised by 1.3%-4.9% [1] - The company has successfully entered into an overseas licensing agreement with Regeneron Pharmaceuticals (REGN.US), which includes an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion [1] Group 2 - The core product Amelot in the oncology sector has received approval in the UK, indicating the company's strong R&D capabilities [2] - Amelot is approved for use as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations, as well as for patients with EGFRT790M mutation-positive NSCLC [2] - The approval in the UK is seen as a solid foundation for further market entry in the EU, despite cautious short-term sales predictions due to competition from AstraZeneca's drug [2]